Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 81/ 100
Competitive context
428 Active assets in the Triple-Negative Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin M.D. Anderson Cancer Center | Phase 4 | BB |
Capivasertib AstraZeneca | Phase 3 | BB |
Cyclophosphamide M.D. Anderson Cancer Center | Phase 4 | BB |
Veliparib National Cancer Institute (NCI) | Phase 3 | BB |
Enzalutamide Nuvation Bio Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →